Moxonidine (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5][6] It may have a role …

2015年10月23日 · Moxonidine is an imidazoline/α-2 receptor agonist used to treat hypertension, especially in cases where ACE inhibitors, β-blockers, calcium channel blockers, and thiazides …

2024年11月8日 · • Moxonidine is a new generation centrally acting antihypertensive agent similar to clonidine that is used in the treatment of increased blood pressure in adults. Why is …

Antihypertensive agent whose site of action is the Central Nervous System (CNS), specifically involving interactions with I1- imidazoline and alpha-2-adrenergic rececptors within the rostral …

Moxonidine and rilmenidine are moderately selective imidazoline agonists which have been in clinical use for several years in many European countries. Trial evidence and postmarketing …

2025年1月7日 · Antihypertensive agent whose site of action is the Central Nervous System (CNS), specifically involving interactions with I1- imidazoline and alpha-2-adrenergic …

View moxonidine information, including dose, uses, side-effects, renal impairment, pregnancy, breast feeding and contra-indications.

Moxonidine is an imidazoline receptor agonist that is highly selective for the I1-imidazoline receptor with little effect at the central alpha2-receptor. Moxonidine has been shown to …

Moxonidine is a selective imidazole II-receptor agonist that lowers BP by a central mechanism but also has been shown to have dose-dependent metabolic effects including reduction in …

Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other …